TENX Files 8-K Furnishing Q2 2025 Financial Results as Exhibit 99.1

Rhea-AI Filing Summary

Tenax Therapeutics has furnished a press release disclosing its financial results for the quarter ended June 30, 2025, attaching that release as Exhibit 99.1 to this Form 8-K. The company also included an interactive XBRL cover page as Exhibit 104 and reconfirmed that the press release is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The 8-K itself does not include any numerical financial figures; readers must consult the attached press release for detailed results and metrics.

Positive

• Disclosure of results via an attached press release (Exhibit 99.1) for the quarter ended June 30, 2025.
• Interactive data included through Exhibit 104 (Cover Page Interactive Data File), supporting data accessibility.

Negative

• No financial figures are included in the 8-K; the filing does not present revenue, earnings, or other metrics.
• The press release is explicitly furnished, not filed, limiting Section 18 liability and not being automatically incorporated by reference into other filings.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished as an exhibit; the 8-K contains no financial figures, so the filing alone does not reveal material results.

The filing confirms Tenax furnished a press release reporting second-quarter results for the period ended June 30, 2025 and attached it as Exhibit 99.1. Because the company states the release is "furnished, not filed," the 8-K does not itself present numeric results or Section 18 filing status protections. From an analyst perspective, the exhibit likely contains the substantive metrics; the 8-K is a procedural notice rather than a source of underlying financial detail.

Corporate Governance Expert

TL;DR: Disclosure was furnished, not filed, which limits Section 18 liability; the 8-K documents the release but provides no financial data within the filing.

The company explicitly attached a press release as Exhibit 99.1 and an interactive XBRL cover page as Exhibit 104. The 8-K reiterates that the release is furnished and not "filed" for Section 18 purposes and will not be incorporated by reference absent explicit mention in a future filing. This is a routine governance disclosure that clarifies legal treatment of the release but does not convey the substance of the reported results within the 8-K itself.

0000034956false00000349562025-08-132025-08-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Tenax Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-34600		26-2593535
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

101 Glen Lennox Drive, Suite 300

Chapel Hill, North Carolina 27517

(Address of principal executive offices) (Zip Code)

919-855-2100

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	TENX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition. 

On August 13, 2025, Tenax Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025.  A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release dated August 13, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 13, 2025	Tenax Therapeutics, Inc.
	By:	/s/ Christopher T. Giordano
		Christopher T. Giordano
		President and Chief Executive Officer

3

FAQ

What did Tenax (TENX) disclose in this Form 8-K?

The company furnished a press release reporting its financial results for the quarter ended June 30, 2025 and attached that release as Exhibit 99.1; the 8-K itself contains no numeric results.

Where can I find Tenax's Q2 2025 financial results?

The detailed results are in the press release attached as Exhibit 99.1 to the Form 8-K.

Is the press release in the 8-K considered 'filed' with the SEC?

No. The company states the press release is furnished, not filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference.

Which exhibits were included with Tenax's 8-K?

Exhibit 99.1 (press release dated August 13, 2025) and Exhibit 104 (Cover Page Interactive Data File).

What is Tenax's ticker and exchange?

Tenax's common stock trades under the ticker TENX on The Nasdaq Stock Market LLC.